Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial

Overview of attention for article published in this source, November 2022

Altmetric Badge

Mentioned by

policy: 1 policy source

twitter: 3 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 12 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Naleving van Covid-19 gedragsmaatregelen door mensen in een kwetsbare positie - geleerde lessen voor pandemische paraatheid

Cited by Rijksinstituut voor Volksgezondheid en Milieu on 02 Dec 2024

RIVM works to prevent and control outbreaks of infectious diseases. We promote public health and consumer safety, and we help to protect the quality of the environment.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.